ArticleCardiovascular toxicology2025
Serum Proteomics Analysis of Patients with Ascending Aortic Dilation.
Article in Cardiovascular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Endothelial Barrier Dysfunction to Circulating Biomarker: Clinical Potential of Claudin-5 in Thoracic Aortic Aneurysm and Dissection.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Ascending aortic dilation (AAD) is a complex and life-threatening condition, representing a significant risk factor for acute aortic syndromes. Due to its asymptomatic nature, early diagnosis is frequently missed. Serum diagnostic biomarkers play a crucial role in disease diagnosis, and proteomics offers a valuable approach for identifying such biomarkers in blood samples. In this study, we collected serum samples from patients with AAD, thoracic ascending aortic dissection (TAAD), and healthy controls, using label-free proteomics to identify serum proteins. Differentially abundant proteins (DAPs) were identified between AAD, TAAD, and control groups. Functional analysis of DAPs was performed using the GO and KEGG databases. Compared to controls, 40 DAPs were found in AAD and 52 in dissection. Further analysis showed that the DAPs in AAD are involved in biological processes such as antibacterial humoral response, nucleosome assembly, and inflammatory response, while the DAPs in TAAD are involved in protein localization to CENP-A containing chromatin and negative regulation of megakaryocyte differentiation, etc. The protein expression profiles of TAAD and AAD were directly compared, leading to the identification of 37 DAPs. GO and KEGG analyses were also performed on these proteins. A significant overlap in protein expression was observed between AAD and dissection. Additionally, NUP188 was significantly down-regulated in AAD, and receiver operating characteristic (ROC) curve analysis suggests it may serve as a diagnostic biomarker for AAD.
Indexed as
Identifiers
40169515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.